Last reviewed · How we verify
Reckitt Benckiser LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mucinex® | Mucinex® | marketed | Expectorant | Respiratory | ||
| Panadeine® Extra | Panadeine® Extra | phase 3 | Opioid analgesic | Opioid receptors | Pain management | |
| Nurofen Plus® | Nurofen Plus® | phase 3 | NSAID/opioid combination analgesic | COX-1/COX-2 (ibuprofen); mu opioid receptor (codeine) | Pain Management |
Therapeutic area mix
- Respiratory · 2
- Pain Management · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- American Health Research · 1 shared drug class
- Archimedes Development Ltd · 1 shared drug class
- Asbjørn Mohr Drewes · 1 shared drug class
- BioDelivery Sciences International · 1 shared drug class
- AdventHealth · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Reckitt Benckiser LLC:
- Reckitt Benckiser LLC pipeline updates — RSS
- Reckitt Benckiser LLC pipeline updates — Atom
- Reckitt Benckiser LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Reckitt Benckiser LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reckitt-benckiser-llc. Accessed 2026-05-14.